NCT05211050

Effect of Sumatriptan on Levcromakalim-Induced Symptoms in Individuals With Migraine

Effect of Sumatriptan on Levcromakalim-Induced Symptoms in Individuals With Migraine: A Randomized Double-Blind Two-Way Crossover Study

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Danish Headache Center · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The study aims to explore the effects of Sumatriptan on Levcromakalim-induced migraine in individuals with migraine without aura.

Detailed description

Opening of adenosine triphosphate-sensitive potassium (KATP) channels using Levcromakalim causes migraine attacks with and without aura in a high proportion of patients. Sumatriptan has been shown to reverse Levcromakalim-induced dilation of the middle meningeal artery and headache in healthy volunteers, indicating that Sumatriptan can overturn the physiological effects of levcromakalim. The study aims to explore the effects of Sumatriptan on Levcromakalim-induced migraine in individuals with migraine without aura.

Conditions

• Migraine Without Aura
• Headache

Interventions

Type	Name	Description
DRUG	Levcromakalim	20 min infusion of 1 mg Levcromakalim followed by either sumatriptan or placebo.
DRUG	Sumatriptan	10 min infusion of 4 mg sumatriptan.
DRUG	Saline	10 min infusion of isotonic saline (placebo).

Timeline

• Start date: 2022-03-15
• Primary completion: 2023-11-05
• Completion: 2023-11-05
• First posted: 2022-01-27
• Last updated: 2025-01-22

Locations

1 site across 1 country: Denmark